Lipiduce 160 Mechanism of Action

Pharmacology: Mechanism of Actions: Systemic: Fenofibrate is a lipid-regulating agent that has chemical, pharmacologic, and clinical similarities to the other fibrate drugs, Clofibrate and Gemfibrozil. Although the exact mechanism of action of Fenofibrate is not completely understood, Fenofibric acid, the active metabolite of Fenofibrate, produces reduction in total cholesterol. LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. Treatment with Fenofibrate also results in increase in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.
Fenofibric acid effects have been explained by the activation of peroxisome proliferator activated receptor alpha (PPARalpha). Through this mechanism, Fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of an inhibitor of lipoprotein lipase activity, apoprotein C-III. The fall in triglycerides produces an alteration in the composition and size of LDL from dense, small particles (possibly atherogenic), to buoyant, large particles. These larger particles are catabolized rapidly due to a greater affinity for cholesterol receptors. An increase in the synthesis of apoproteins A-I, A-II, and HDL-cholesterol also results by activation of PPARalpha.
Fenofibrate reduces serum uric acid concentrations in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.
Pharmacokinetics: Absorption: Effect on food, micronized Fenofibrate: no effect.
Distribution: Vd: 30L.
Metabolism: Systemic: active metabolite: Fenofibric acid.
Excretion: Systemic: Fecal: 25%; Renal: 60% metabolites.
Elimination: Half-life: Fenofibric acid, mean 20 hours (range 10-35 hours).